How do I get Boncresa
through my insurance?
Boncresa · denosumab-mobz · interchangeable Prolia biosimilar · provider-administered 60 mg SC every 6 months
No account, member ID, name, date of birth or email is needed for this beta. Your selections stay in this page session.
Choose the diagnosis / reason.
The same drug family can have different medical-necessity requirements depending on why it is prescribed.
“Denosumab is covered” is only half the answer.
Medical necessity
The plan first asks whether the selected diagnosis meets its denosumab coverage criteria — fracture risk, bone density, prior therapy, steroid use, ADT or aromatase-inhibitor treatment depending on the indication.
Product preference
Then the plan may require a particular denosumab product. A request for Boncresa can be medically appropriate but still need a preferred-product exception if the plan favors another reference/biosimilar product.
Then solve the patient’s out-of-pocket cost.
The assistance program has to match the exact product that will actually be authorized and administered. That is why MedicineCostHelp puts coverage and biosimilar preference before copay assistance.
FDA Purple Book product record →What people actually need to know.
How do I get Boncresa through my insurance?
Choose the diagnosis and insurance type above. MedicineCostHelp then connects the request to the insurer’s current medical-benefit policy and, when available, its denosumab product-preference rule. Your individual benefit plan and authorization decision still control.
Is Boncresa a biosimilar to Prolia?
Yes. FDA lists Boncresa (denosumab-mobz) as an interchangeable biosimilar to Prolia. The insurer can still have product-preference and prior-authorization rules, so the requested brand and the covered brand may not be the same.
Why does the billing code matter?
Each denosumab product may have a product-specific HCPCS code or may temporarily require an unclassified code. The clinic has to bill the product actually administered with current payer/CMS coding. MedicineCostHelp shows the code we last verified but tells the treatment site to confirm it before billing.
Is this the same coverage path as Xgeva?
No. Prolia-type denosumab uses 60 mg every six months for osteoporosis and specified treatment-related bone loss. Xgeva-type denosumab uses different dosing and oncology/metabolic-bone indications, so MedicineCostHelp treats it as a separate path.
Important
MedicineCostHelp is an educational navigation tool, not an insurer and not a coverage determination. The member’s benefit plan, medical necessity, prior authorization, product preference, current billing code and site-of-care rules can change the outcome. Product and policy sources in this beta were checked August 20, 2026.